Business
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively.Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR, SMNRW) , a clinical late-stage specialty pharmaceutical company focused on the development and comm
About this update from Scilex Holding Company
[{"type":"image","alt":"Semnur Pharmaceuticals","displaySize":"","headline":null,"caption":"Semnur Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":162,"height":66,"url":"https://media.zenfs.com/en/globenewswire.com/373cf12648197dcd1afb9fce5c66076c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8ewlcT4OtzbnyX731K4c4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTg2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/373cf12648197dcd1afb9fce5c66076c","width":162,"height":66}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively.","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination","length":111,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":277,"olType":false},{"type":"text","content":"PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR, SMNRW) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and Denali Capital Acquisition Corp (“Denali”), a special purpose acquisition company, announced the closing of their previously announced business combination (the "Business Combination") on September 22, 2025.","length":492,"tagName":"p"},{"type":"text","content":"The combined company will operate as “Semnur Pharmaceuticals, Inc.” and its shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively.","length":233,"tagName":"p"},{"type":"text","content":"“Semnur is entering an exciting phase as the resources of the public capital markets will be available to enhance our business growth and enable us to continue to fulfill our mission to address patient non-opioid pain management needs”, said Henry Ji, Ph.D., Executive Chairperson of Semnur. “Our unique model continues to demonstrate the multiple ways in which we can unlock value for our stockholders. We appreciate our partnership with the team at Denali as we prepare for this next chapter.”","len...